# Nivolumab

## Opdivo inj 100mg/10mL

| TAH Drug Code      | [**IOPD**](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IOPD)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Unresectable or Metastatic Melanoma. Adjuvant Treatment of Melanoma. Metastatic Non-Small Cell Lung Cancer. Advanced Renal Cell Carcinoma. Classical Hodgkin Lymphoma. Squamous Cell Carcinoma of the Head and Neck. Urothelial Carcinoma. Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient. Hepatocellular Carcinoma.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Dosing             | Monotherapy: [Melanoma, unresectable or metastatic; Non-small cell lung cancer, metastatic, progressive; Renal cell carcinoma, advanced; Hodgkin lymphoma, classical; Head and neck cancer, squamous cell; Urothelial carcinoma, locally advanced or metastatic; Gastric cancer or gastroesophageal junction cancer, advanced or metastatic; Hepatocellular carcinoma; Colorectal cancer, metastatic, microsatellite instability-high or mismatch repair deficient] 3 mg/kg infused over 30 minutes once every 2 weeks until disease progression or unacceptable toxicity. [Esophageal carcinoma, squamous cell, unresectable advanced, recurrent, or metastatic] 240 mg infused over 30 minutes once every 2 weeks until disease recurrence or unacceptable toxicity. [Melanoma, adjuvant treatment] 3 mg/kg infused over 30 minutes once every 2 weeks until disease recurrence or unacceptable toxicity for up to 1 year. Combination therapy: [Melanoma, unresectable or metastatic] 1 mg/kg once every 3 weeks in combination with ipilimumab 3 mg/kg over 90 minutes for a maximum of 4 combination doses or until unacceptable toxicity (whichever occurs earlier), followed by nivolumab 3 mg/kg once every 2 weeks until disease progression or unacceptable toxicity. [Non-small cell lung cancer, metastatic, PD-L1-expressing] 3 mg/kg once every 2 weeks in combination with ipilimumab 1 mg/kg once every 6 weeks until disease progression, unacceptable toxicity or for up to 2 years in patients without disease progression. [Non-small cell lung cancer, metastatic or recurrent] 360 mg once every 3 weeks in combination with ipilimumab 1 mg/kg every 6 weeks and histology-based platinum-doublet chemotherapy every 3 weeks until disease progression, unacceptable toxicity or for up to 2 years in patients without disease progression. [Renal cell carcinoma, advanced, first-line treatment; intermediate or poor risk] 3 mg/kg once every 3 weeks in combination with ipilimumab 1 mg/kg over 30 minutes for 4 combination doses, followed by 3 mg/kg once every 2 weeks (nivolumab monotherapy) until disease progression or unacceptable toxicity. [Colorectal cancer, metastatic, microsatellite instability-high or mismatch repair deficient] 3 mg/kg once every 3 weeks in combination with ipilimumab 1 mg/kg over 30 minutes for 4 combination doses, followed by 3 mg/kg once every 2 weeks (nivolumab monotherapy) until disease progression or unacceptable toxicity. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Contraindications  | Specific contraindications have not been determined.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Adverse Effects    | Common Hypertension (36% ), Hand-foot syndrome due to cytotoxic therapy (40% ), Pruritus (10% to 53% ), Rash (16% to 53% ), Hyperglycemia (6% to 19% ), Abdominal pain (10% to 34% ), Constipation (10% or greater ), Decrease in appetite (14% to 35% ), Nausea (16% to 34% ), Stomatitis (Up to 37% ), Vomiting (12% to 31% ), Arthralgia (10% to 23% ), Backache (Renal cell carcinoma, 21% ), Musculoskeletal pain (17% to 42% ), Headache (11% to 23% ), Neuropathy (Up to 12% ), Cough (10% to 37% ), Dyspnea (2% or greater ), Upper respiratory infection (9% to 44% ), Fatigue (12% or 62% ). Serious Myocarditis, Pericarditis, Shock, Vasculitis, Erythroderma, Stevens-Johnson syndrome, Toxic epidermal necrolysis, Adrenal insufficiency (0.6% to 18% ), Diabetic ketoacidosis (0.1% ), Hyperthyroidism (2.7% to 12% ), Hypophysitis (0.6% to 9% ), Hypopituitarism, Hypothyroidism (4.5% to 34% ), Thyroiditis (0.6% ), Type 1 diabetes mellitus (0.9% ), Colitis (1.9% to 26% ), Diarrhea (17% to 64% ), Duodenitis, Esophageal fistula, Fatal (0.5% ), Gastritis, Gastrointestinal hemorrhage, Fatal (0.5% ), Pancreatitis, Perforation of colon (Less than 10% ), Aplastic anemia, Autoimmune hemolytic anemia, Hemoptysis, Massive, Idiopathic thrombocytopenic purpura, Thrombocytopenia, Hepatitis (1.8% to 21% ), Hepatotoxicity (44% ), Veno-occlusive disease of the liver, Graft versus host disease, Histiocytic necrotizing lymphadenitis, Sarcoidosis, Transplanted organ rejection, Arthritis, Eaton-Lambert syndrome, Myasthenia gravis, Myositis, Polymyalgia rheumatica, Polymyositis, Rhabdomyolysis, Demyelination of spinal cord, Encephalitis, Guillain-Barre syndrome, Meningitis, Myelitis, Iritis, Myasthenia gravis, ocular, Unexplained visual loss, Uveitis (0.8% ), Vogt-Koyanagi-Harada disease, Nephritis, Renal impairment, Urinary tract infectious disease (Urothelial carcinoma, 17% ), Interstitial lung disease (16% ), Pleural effusion (2% or greater ), Pneumonia (2% or greater ), Pneumonitis (1.3% to 10% ), Pulmonary embolism (Non-small cell lung cancer, recurrent, 4.2% ), Respiratory failure (2% or greater ), Respiratory tract infection (2% or greater ) Other: Cytomegalovirus infection, Disorder characterized by fever, Steroid-requiring, Sepsis (2% or greater )                                                                                                                                                                      |
| Pregnancy          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

